A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,024actual
Sites
196
Countries
Argentina, Australia, Canada +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-16 | actual | When the study began enrolling |
| Primary completion | 2026-03-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-06 | actual | The whole study's end, after follow-up |
| First posted | 2024-01-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Interventions
- Drug: Cagrilintide
- Drug: Semaglutide
- Drug: Tirzepatide
Primary outcomes
what the primary-completion date above is the date OFChange in glycated haemoglobin (HbA1c)
measured From baseline (week 0) to end of treatment (week 68)
Relative change in body weight
measured From baseline (week 0) to end of treatment (week 68)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed